NFL Biosciences SA
ALNFL
Company Profile
Business description
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Contact
199 rue Helene Boucher
Castelnau-le-Lez34170
FRAT: +33 411937667
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
4
Stocks News & Analysis
stocks
Chart of the Week: Aussie dividend yields are less attractive than alternatives
The latest insights from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,854.90 | 11.80 | 0.13% |
| CAC 40 | 8,086.05 | 20.11 | -0.25% |
| DAX 40 | 23,960.59 | 116.28 | -0.48% |
| Dow JONES (US) | 47,885.97 | 228.29 | -0.47% |
| FTSE 100 | 9,774.32 | 89.53 | 0.92% |
| HKSE | 25,436.60 | 32.18 | -0.13% |
| NASDAQ | 22,693.32 | 418.14 | -1.81% |
| Nikkei 225 | 49,006.89 | 505.39 | -1.02% |
| NZX 50 Index | 13,247.06 | 48.85 | -0.37% |
| S&P 500 | 6,721.43 | 78.83 | -1.16% |
| S&P/ASX 200 | 8,568.90 | 12.40 | 0.14% |
| SSE Composite Index | 3,875.97 | 5.69 | 0.15% |